Genelux (NASDAQ:GNLX) and Cyclerion Therapeutics (NASDAQ:CYCN) Head-To-Head Survey

Cyclerion Therapeutics (NASDAQ:CYCN) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation and earnings.

Valuation & Earnings

This table compares Cyclerion Therapeutics and Genelux’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclerion Therapeutics	$1.62 million	3.85	-$5.26 million	N/A	N/A
Genelux	$170,000.00	371.79	-$28.30 million	($0.97)	-1.90

Cyclerion Therapeutics has higher revenue and earnings than Genelux.

Volatility and Risk

Cyclerion Therapeutics has a beta of 1.85, indicating that its share price is 85% more volatile than the S&P 500. Comparatively, Genelux has a beta of -1.57, indicating that its share price is 257% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Cyclerion Therapeutics and Genelux, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclerion Therapeutics	0	0	0	0	N/A
Genelux	0	0	4	0	3.00

Genelux has a consensus target price of $32.33, indicating a potential upside of 1,657.25%. Given Genelux’s higher probable upside, analysts plainly believe Genelux is more favorable than Cyclerion Therapeutics.

Profitability

This table compares Cyclerion Therapeutics and Genelux’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cyclerion Therapeutics	N/A	-77.93%	-61.09%
Genelux	N/A	-125.58%	-86.03%

Institutional & Insider Ownership

75.6% of Cyclerion Therapeutics shares are owned by institutional investors. Comparatively, 37.3% of Genelux shares are owned by institutional investors. 13.1% of Cyclerion Therapeutics shares are owned by insiders. Comparatively, 9.3% of Genelux shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Cyclerion Therapeutics beats Genelux on 7 of the 10 factors compared between the two stocks.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.